Clinical bottom line
Novel RNA-based therapeutics represent a promising frontier in the management of arrhythmias associated with genetic and acquired cardiomyopathies. By targeting pathogenic gene expression and modulating molecular pathways implicated in arrhythmogenesis, these therapies offer a potential strategy to reduce arrhythmia burden and improve clinical outcomes. However, current evidence remains largely preclinical or early-phase, and clinical validation is needed before routine adoption. Clinicians should remain informed about ongoing developments while recognizing the experimental nature of RNA therapeutics in this context.
What the evidence shows
Arrhythmias are a major cause of morbidity and mortality in patients with cardiomyopathies, often driven by genetic mutations or remodeling processes that alter cardiac electrophysiology (Sharif Zain et al., 2021; TAŞ ALPEREN et al., 2026). Conventional management includes pharmacologic antiarrhythmics, device therapy, and ablation, but these approaches may be limited by incomplete efficacy or adverse effects (Sharif Zain et al., 2021).
RNA-based therapeutics, including small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and microRNA modulators, offer targeted suppression or modulation of disease-causing transcripts. Preclinical studies have demonstrated that RNA interference can downregulate mutant or deleterious gene products implicated in inherited cardiomyopathies, potentially normalizing ion channel expression and reducing arrhythmogenic substrate (Leviner et al., 2015). For example, RNA interference strategies targeting pathogenic variants in genes encoding sarcomeric proteins or ion channels have shown promise in cellular and animal models by mitigating arrhythmia triggers (Leviner et al., 2015).
Furthermore, RNA therapeutics may address arrhythmia-induced cardiomyopathy by modulating molecular pathways involved in maladaptive remodeling and fibrosis, which contribute to arrhythmia persistence and progression (Dhawan et al., 2020; TAŞ ALPEREN et al., 2026). This dual action—targeting both genetic drivers and secondary remodeling—positions RNA-based approaches as a potentially transformative modality.
While RNA-based therapies have been extensively explored in neurodegenerative diseases with encouraging results (Mahjoubin-Tehran et al., 2026), their application in cardiomyopathies remains in early translational stages. Safety, delivery mechanisms, and long-term efficacy require further elucidation. Nonetheless, the mechanistic rationale and preclinical data support continued investigation.
Caveats and uncertainty
Clinical data on RNA-based therapeutics for arrhythmia management in cardiomyopathies are currently limited. Most evidence derives from in vitro or animal models, which may not fully replicate human disease complexity or predict clinical efficacy. The heterogeneity of cardiomyopathy etiologies and arrhythmia mechanisms further complicates patient selection and therapeutic targeting.
Delivery of RNA therapeutics to cardiac tissue poses challenges, including achieving sufficient myocardial uptake, avoiding off-target effects, and minimizing immune responses. Long-term safety profiles remain unknown, particularly regarding potential effects on cardiac function or unintended gene modulation.
Additionally, the timing of intervention—whether early in disease course or after arrhythmia manifestation—may influence outcomes but has not been systematically studied. Integration with existing therapies and impact on hard clinical endpoints such as sudden cardiac death or heart failure progression require rigorous clinical trials.
How this may change practice
If ongoing and future clinical studies validate safety and efficacy, RNA-based therapeutics could augment current arrhythmia management paradigms in cardiomyopathy patients by providing a precision medicine approach targeting underlying molecular causes. This may reduce reliance on symptomatic treatments and invasive procedures, potentially improving quality of life and prognosis.
In practice, cardiologists may incorporate genetic and molecular profiling to identify candidates for RNA-based interventions. Multidisciplinary collaboration with molecular cardiology and pharmacology specialists will be essential for patient selection and monitoring.
Until robust clinical evidence emerges, RNA therapeutics should be considered investigational. Clinicians should counsel patients accordingly and consider enrollment in clinical trials when available. Awareness of this evolving field will prepare practitioners for integration of novel RNA-based options as they transition from bench to bedside.